BRPI0411525A - composto - Google Patents

composto

Info

Publication number
BRPI0411525A
BRPI0411525A BRPI0411525-2A BRPI0411525A BRPI0411525A BR PI0411525 A BRPI0411525 A BR PI0411525A BR PI0411525 A BRPI0411525 A BR PI0411525A BR PI0411525 A BRPI0411525 A BR PI0411525A
Authority
BR
Brazil
Prior art keywords
phenylethyl
amino
propanoic acid
ethoxy
hexyl
Prior art date
Application number
BRPI0411525-2A
Other languages
English (en)
Inventor
Carl-Johan Aurell
Dahlstr M Mikael
Eva-Lotte Lindstedt Alstermark
Anna Minidis
Bengt Ohlsson
Erica Stahle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0411525A publication Critical patent/BRPI0411525A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"COMPOSTO". Um composto selecionado a partir de um ou mais dos seguintes: um sal de (1R, 2S)-2-hidroxiindan-1-amina do ácido (2S)-2- etóxi3-(4-{2-¢hexil(2-feniletil) amino!-2-oxoetóxi} fenil propanóico; um sal de L-arginina do ácido (2S)-2- etóxi-3-(4-{2-¢hexil(2-feniletil) amino!-1-oxoetóxi} fenil)propanóico; um sal de L-arginina do ácido (2S)-2-etóxi-3-(4-{2-hexil(2-feniletil) amino-2-oxoetoxifenil) propanóico; um sal de terc-butilamina do ácido (2S)-2-etóxi-3-(4-{2-¢hexil(2-feniletil) amino-2-oxoetoxifenil) propanóico; um sal de colina de (2S)-2-etóxi-3-(4-{2-¢hexil(2-feniletil) amino!-2-oxoetóxi} fenil propanóico; um sal de adamantilamina do ácido (2S)-2- etóxi-3-(4- {2-¢hexil(2-feniletil) amino!-2-oxoetóxi} fenil) propanóico; um sal de N-benzil-2-feniletanamínio de (2S)-2-etóxi-3-(4-¢2-¢hexil(2-feniletil) amino!-2-oxoetóxi} fenil) propanóico; um sal de N-benzil-2-(benzilamino) etanamínio do ácido (2S)-2-etóxi-3-(4-¢2-¢hexil(2-feniletil) amino!-2-oxoetóxi} fenil) propanóico; ou um sal de tris(hidroximetil)metilamina do ácido (2S)-2-etóxi-3-(4-{2-¢hexil(2-feniletil) amino!-2-oxoetóxi} fenil)propanóico.
BRPI0411525-2A 2003-06-18 2004-06-16 composto BRPI0411525A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0314129.8A GB0314129D0 (en) 2003-06-18 2003-06-18 Therapeutic agents
PCT/SE2004/000964 WO2004110984A1 (en) 2003-06-18 2004-06-16 Pharmaceutically useful salts of carboxylic acid derivates

Publications (1)

Publication Number Publication Date
BRPI0411525A true BRPI0411525A (pt) 2006-08-01

Family

ID=27636788

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411525-2A BRPI0411525A (pt) 2003-06-18 2004-06-16 composto

Country Status (23)

Country Link
US (1) US20060142389A1 (pt)
EP (1) EP1638922A1 (pt)
JP (1) JP3822900B1 (pt)
KR (1) KR20060027348A (pt)
CN (1) CN1809529A (pt)
AR (1) AR044801A1 (pt)
AU (1) AU2004247610B2 (pt)
BR (1) BRPI0411525A (pt)
CA (1) CA2528932A1 (pt)
CO (1) CO5650228A2 (pt)
GB (1) GB0314129D0 (pt)
IL (1) IL172167A0 (pt)
IS (1) IS8231A (pt)
MX (1) MXPA05013714A (pt)
MY (1) MY137277A (pt)
NO (1) NO20055922L (pt)
RU (1) RU2005138590A (pt)
SA (1) SA04250169B1 (pt)
TW (1) TW200503677A (pt)
UA (1) UA81807C2 (pt)
UY (1) UY28375A1 (pt)
WO (1) WO2004110984A1 (pt)
ZA (1) ZA200510252B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) * 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
BR0311932A (pt) 2002-06-20 2005-03-22 Astrazeneca Ab Composto, formulação farmacêutica, método para tratar ou prevenir resistência à insulina, uso de um composto, processo para preparar um composto, e, tratamento combinado
SE0403072D0 (sv) * 2004-12-16 2004-12-16 Astrazeneca Ab Pharmaceutically useful salts of carboxylic acid derivates
WO2007004957A1 (en) * 2005-07-05 2007-01-11 Astrazeneca Ab Novel crystalline form
AR055073A1 (es) * 2005-07-11 2007-08-01 Astrazeneca Ab Agentes terapeuticos
NO2686520T3 (pt) 2011-06-06 2018-03-17
WO2012170439A1 (en) 2011-06-06 2012-12-13 The Ohio State University Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
JP2016521747A (ja) 2013-06-13 2016-07-25 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 貧血治療のための組成物及び方法
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US10150734B2 (en) 2015-01-23 2018-12-11 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
WO2021117767A1 (ja) 2019-12-10 2021-06-17 田辺三菱製薬株式会社 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2219172C2 (ru) * 1999-04-06 2003-12-20 Санкио Компани, Лимитед α-ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
RU2005138590A (ru) 2006-07-27
IS8231A (is) 2006-01-13
SA04250169A (ar) 2005-12-03
CO5650228A2 (es) 2006-06-30
MY137277A (en) 2009-01-30
AU2004247610A1 (en) 2004-12-23
IL172167A0 (en) 2009-02-11
ZA200510252B (en) 2006-12-27
GB0314129D0 (en) 2003-07-23
SA04250169B1 (ar) 2007-08-07
UY28375A1 (es) 2005-01-31
EP1638922A1 (en) 2006-03-29
MXPA05013714A (es) 2006-06-27
JP2006527766A (ja) 2006-12-07
KR20060027348A (ko) 2006-03-27
JP3822900B1 (ja) 2006-09-20
UA81807C2 (uk) 2008-02-11
CA2528932A1 (en) 2004-12-23
TW200503677A (en) 2005-02-01
CN1809529A (zh) 2006-07-26
AU2004247610B2 (en) 2008-04-17
NO20055922L (no) 2006-01-06
US20060142389A1 (en) 2006-06-29
AR044801A1 (es) 2005-10-05
WO2004110984A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
BRPI0411525A (pt) composto
MA29416B1 (fr) Inhibiteurs d'age
UA100966C2 (ru) Фармацевтическая композиция на основе 2-[4-(4-хлорбензоил)фенокси]-2-метилпропионовой кислоты и ее солей
BR9815464A (pt) Polìmero, processo de preparação de polìmeros, utilização de um polìmero, composição, associação de pelo menos um polìmero com pelo menos um composto e composição cosmética
DE602004032118D1 (de) Aminophosphonsäurederivate, deren additionssalze und s1p-rezeptormodulatoren
BR9912494A (pt) Derivado de di ou trifluorometanossulfonil anilida, processo para a sua produção e herbicida contendo o referido derivado como ingrediente ativo
DE602004024545D1 (de) Indungen
TW200635585A (en) Monocyclic substituted methanones
NO20073755L (no) Ibandronatpolymorf B
MY148953A (en) Substituted biphenyl carboxylic acids and derivatives thereof
BRPI0509982A8 (pt) cepa isolada de escherichia coli, e, método para produzir um composto
NO20055923L (no) Farmasoytisk anvendbare salter av karboksylsyrderivater
DE602006008962D1 (de) Verfahren zur herstellung von valsartan
AR052894A1 (es) Derivado de diazabiciclononeno
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
TH69682A (th) สารบำบัด
AR044267A1 (es) Compuesto intermedio util para la preparacion de pioglitazona
TW200635911A (en) Sulfanyl substituted phenyl methanones
HRP20060079B1 (en) Benzoquinolizine-2-carboxylic acid arginine salt tetrahydrate
BRPI0519029A2 (pt) composto, uso do mesmo, e, composiÇço farmacÊutica
TH81758A (th) เกลือของอนุพันธ์คาร์บอกซิลิคแอซิดที่มีประโยชน์ในทางเภสัชกรรม
BR0009783A (pt) Sais de ácido fosfórico de uma diamina aromática
BR0110642A (pt) Processo para preparação de sais de sulfonilbenzoilguanidìnio
UY29268A1 (es) Sales farmaceuticamente aceptables de derivados de acido carboxilico
AU2003263378A1 (en) Benzenesulphonamides and process for their preparation

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.